Voyager Therapeutics (VYGR) Tops Q3 EPS by 29c

Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.16), $0.29 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.63 million versus the consensus estimate of $11.7 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 22nd Century Group files prospectus for warrant share resale
• Lantern Pharma (LTRN) files for 2.24M share offering by selling stockholders